Antoni Martínez-Rubio

Antoni Martínez-Rubio

University Hospital of Sabadell, Sabadell, Spain

Biography

Dr Antoni Martinez Rubio , Jefe de Servicio de Cardiología del Hospital Parc Taulí de Sabadell (Barcelona, España).

Reasearch areas

Atrial Fibrillation

Coronary Artery Disease and Myocardial Infarction

Articles

Coronavirus Disease 2019 and Cardiac Arrhythmias

Antoni Martínez-Rubio, Soledad Ascoeta, Fadwa Taibi, et al

Published:

Citation: European Cardiology Review 2020;15:e66.

Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic

M Rizzo, I Colomer-Asenjo, M Sutil-Vega, et al

Citation: European Cardiology Review 2020;15:e31.

Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction

M Rizzo, I Colomer-Asenjo, G Cabello-Molina, et al

Citation: European Cardiology Review 2020;15:e32.

Differences in Clinical Characteristics, Results and Management of Patients Referred for Pharmacologic Cardiac Stress SPECT Depending on the Protocol Used

Pablo Del Castillo-Vásquez, Núria Casanovas, Marcel Santaló-Corcoy, et al

Citation: European Cardiology Review 2017;12(2):102.

Secondary Prevention in Patients with Non Valvular Atrial Fibrillation and Previous Stroke. Is It Possible to Have an Appropriate INR Control?

Mario DiazNuila-Alcazar, Daniel Valcárcel-Paz, Marcel Santaló-Corcoy, et al

Citation: European Cardiology Review 2017;12(2):103.

Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation: Assessment, Monitoring and Treatment Reversal

Antoni Martínez-Rubio, Mario DiazNuila-Alcazar, Anna Soria Cadena, et al

Published:

Citation: European Cardiology Review 2016;11(2):118–22

Cardiovascular Pharmacotherapies Focus: Are low doses of direct-acting oral anticoagulants justified and appropriate in patients with nonvalvular atrial fibrillation?

Antoni Martínez-Rubio, Gheorghe-Andrei Dan,

Citation: European Cardiology Review 2016;11(2):115–7

Key Recent Advances in Atherosclerosis Treatment with Modern Lipid-lowering Drugs: The New Frontier with PCSK9 Inhibitors

Antoni Martínez-Rubio, Román Freixa Pamias,

Citation: European Cardiology Review 2017;12(1):30–2